In randomized patients, median (range) duration of exposure to long-acting pasireotide in patients with acromegaly was 5.5 (3.7–7.6) months in the incretin-based therapy arm and 5.5 (4.2–8.0) months in the insulin arm. Here, INS is linked to acromegaly.